McAreavey Pharma Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: NI674652

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		186,162		223,395
Tangible Assets	5		10,520		16,675

			196,682		240,070
CURRENT ASSETS
Stocks	6	25,000		28,016
Debtors	7	132,888		120,947
Cash at bank and in hand		45,347		45,563

		203,235		194,526
Creditors: Amounts Falling Due Within One Year	8	(203,866 )		(180,603 )

NET CURRENT ASSETS (LIABILITIES)			(631 )		13,923

TOTAL ASSETS LESS CURRENT LIABILITIES			196,051		253,993

Creditors: Amounts Falling Due After More Than One Year	9		(123,333 )		(163,333 )

NET ASSETS			72,718		90,660

CAPITAL AND RESERVES
Called up share capital			1		1
Profit and Loss Account			72,717		90,659

SHAREHOLDERS' FUNDS			72,718		90,660

Page 1

Page 2

McAreavey Pharma Ltd

Balance Sheet (continued)

As At 31 December 2025

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mrs Orfhlaith McAreavey

Director

30/04/2026

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

McAreavey Pharma Ltd is a private company, limited by shares, incorporated in Northern Ireland, registered number NI674652 . The registered office is 505 Falls Road , Belfast, BT12 6DE.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Revenue from Sale of goods

Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.

2.3. Intangible Fixed Assets and Amortisation - Other Intangible

Other intangible assets are goodwill. It is amortised to profit and loss account over its estimated economic life of 10 years.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings

20% Straight Line

2.5. Stocks and Work in Progress

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 8 (2024: 6)

4. Intangible Assets

	Other
	£
Cost
As at 1 January 2025	372,327

As at 31 December 2025	372,327

Amortisation
As at 1 January 2025	148,932
Provided during the period	37,233

As at 31 December 2025	186,165

Net Book Value
As at 31 December 2025	186,162

As at 1 January 2025	223,395

Page 3

Page 4

McAreavey Pharma Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2025

5. Tangible Assets

	Fixtures & Fittings
	£
Cost
As at 1 January 2025	47,327
Additions	3,798

As at 31 December 2025	51,125

Depreciation
As at 1 January 2025	30,652
Provided during the period	9,953

As at 31 December 2025	40,605

Net Book Value
As at 31 December 2025	10,520

As at 1 January 2025	16,675

6. Stocks

	2025	2024
	£	£
Stock	25,000	28,016

7. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	54,000	54,256
Other debtors	78,888	66,691

	132,888	120,947

8. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	72,000	49,224
Bank loans and overdrafts	40,000	40,000
Amounts owed to group undertakings	50,888	-
Amounts owed to participating interests	-	53,888
Other creditors	2,861	2,914
Taxation and social security	38,117	34,577

	203,866	180,603

9. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Bank loans	123,333	163,333

Page 4

Page 5

McAreavey Pharma Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2025

10. Related Party Transactions

Included in other creditors are amounts due to related party of £50,888 (2024: £53,888). The debt is being repaid monthly and no interest is being charged.

Page 5